DISC-0974

Disc Medicine has initiated the APOLLO confirmatory trial for bitopertin in erythropoietic protoporphyria (EPP) and remains on track to submit an NDA under accelerated approval pathway in the second half of 2025.

Disc Medicine is preparing for an NDA submission for bitopertin in erythropoietic protoporphyria (EPP) following positive FDA feedback, potentially leading to accelerated approval.

Disc Medicine presented Phase 1b trial results of DISC-0974 for myelofibrosis-associated anemia at the ASH annual meeting, showing significant clinical benefits.

Disc Medicine has obtained a $200 million non-dilutive term loan to support its clinical trials and enhance financial flexibility.

Disc Medicine received positive feedback from the FDA regarding bitopertin for erythropoietic protoporphyria (EPP), potentially allowing for accelerated approval based on PPIX reduction.